Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1

NCT03525392 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03525392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03525392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1
Lead sponsor
Ipsen
Phase
Phase 1
Overall status
Terminated
Start date
May 3, 2018
Completion date
April 28, 2021
Enrollment
14 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, bone cancer, colorectal cancer, gastric cancer, metastatic tumours, pancreatic ductal adenocarcinoma, recurrent disease, squamous cell carcinoma of the head and neck